Julie 2022: Volgens die mees onlangse navorsing wat deur Emergen Research gedoen is, het die wêreldmark vir CAR T-selle-terapie 'n grootte van USD 1.29 miljard in 2021 bereik en sal na verwagting 'n inkomste-CAGR van 24.9 persent in die loop van die voorspellingsperiode registreer. Die stygende voorkoms van kanker oor die hele wêreld, sowel as die groeiende sterftesyfer wat deur kanker veroorsaak word, sal na verwagting in die loop van die voorspellingsperiode die primêre drywers van inkomstegroei in die wêreldwye CAR-T-selterapiemark wees. Die uitbreiding van kliniese proefaktiwiteite teen 'n yslike tempo, die verspreiding van samesmeltings en verkrygings, en die aanloklikheid van aanvanklike openbare aanbiedinge is alles faktore wat bydra tot die groei van inkomste in die wêreldwye CAR T-selterapiemark.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global MOTOR T-Sel terapie market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the MOTOR T-Sel terapie market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Bykomende betekenisvolle bevindinge uit die verslag dui daarop dat
In 2021, the segment of diffuse large B-cell limfoom was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with chimeriese antigeen reseptor T-sel terapie, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell nie-Hodgkin limfome who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Die sleutelmaatskappye wat tans in die mark werk, word verder in hierdie verslag ondersoek, asook hul maatskappyprofiele, produkportefeuljes, uitbreidingstrategieë en strategiese alliansies. Enkele voorbeelde van hierdie tipe alliansies sluit in samesmeltings en verkrygings, samewerkings en gesamentlike ondernemings. Hierbenewens verskaf dit hoogtepunte oor die maatskappy se prestasies en finansiële stand, asook insigte oor die markbereik en globale posisie van die maatskappy.
Maatskappye wat geprofileer is in die wêreldwye CAR T-Cell Therapy-mark:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd., Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., en Eli Lilly and Company .
Lees meer oor die wêreldwye CAR T-Cell Therapy-markverslag by: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
